Pharma Tech Trends and Development Cost Solutions
News Apr 04, 2013
The free webinar lays out the pressures currently being faced by the industry—including cost and regulatory pressures—and explores the chemistry workflows and emerging technologies that are helping industry participants address these challenges, remain competitive, and protect profits.
With the reality of patent cliffs, regulatory standards, attrition, and globalization, companies are learning to work fast and “lean” without sacrificing effectiveness and safety. In the webinar, targeted technology application and the methodologies it enables results in an ability to handle increased experiment volume—the kind that will be required for success if pharmaceutical industry trends continue—while lowering development and production costs.
Accounting for issues such as inherited chemistry, variable yields, and long development cycles, the webinar looks at real-world examples of industry giants such as Pfizer using technologies that help understand particle and reaction characteristics for significant process enhancement. In situ mid-IR spectroscopy and Focus Beam Reflectance Measurement (FBRM®)—as well as workstations that incorporate them—are shown to illuminate particle growth/crystallization and other critical reaction characteristics to shorten cycle times, increase yields, enhance safety, and ease scale-up. One production initiation example lowered costs by at least $.5M—a savings that will compound with each successive use of the equipment.
Reaction Progress Kinetics Analysis is also discussed in detail. This methodology, developed by Professor Donna Blackmond who is currently with Scripps Research Institute, allowed researchers to develop a kinetic model in significantly fewer experiments over traditional methods, which in turn helped optimize a synthetic route for enhanced commercial viability.
Ingenza Advances inABLE® Biomanufacturing Technologies in Collaboration with SyngentaNews
Ingenza has reached a major technical milestone with Syngenta in their collaboration to develop efficient manufacturing technologies for innovative crop protection products.READ MORE
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018